Bladder cancer and Th1 chemokines
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
La Clinica Terapeutica
|May 11, 2017
Summary
Bacillus Calmette–Guérin (BCG) immunotherapy for bladder cancer triggers a T helper 1 immune response. This response, marked by elevated IP-10 and Interferon-gamma in urine, may inhibit tumor growth and angiogenesis.
Area of Science:
- Uro-oncology
- Immunology
- Cancer research
Background:
- Bladder cancer, or transitional cell carcinoma (TCC), is linked to smoking and occupational carcinogen exposure.
- Intravesicular Bacillus Calmette–Guérin (BCG) immunotherapy is a standard treatment for superficial bladder cancer.
- Successful BCG treatment relies on inducing a T helper 1 (Th1) immune response.
Purpose of the Study:
- To investigate the role of IP-10 and Interferon-gamma (IFN-γ) in BCG immunotherapy for bladder cancer.
- To explore the anti-angiogenic properties of the urinary microenvironment induced by intravesicular BCG.
- To assess the potential of IP-10 as a prognostic marker in bladder cancer patients undergoing BCG therapy.
Main Methods:
- Analysis of urinary IP-10 and IFN-γ levels in bladder cancer patients post-intravesicular BCG treatment.
- In vitro stimulation of TCC and endothelial cell lines with BCG or IFN to assess IP-10 secretion.
- Evaluation of the anti-angiogenic effects of the BCG-induced urinary microenvironment.
Main Results:
- Elevated levels of IP-10 and IFN-γ were detected in the urine of bladder cancer patients after BCG immunotherapy.
- Both TCC and endothelial cells demonstrated the ability to secrete IP-10 when stimulated with BCG or IFN in vitro.
- Intravesicular BCG was found to induce a Th1 chemokine-rich urinary environment that inhibits endothelial cells, suggesting anti-angiogenic activity.
Conclusions:
- BCG immunotherapy for bladder cancer successfully induces a Th1 immune response, characterized by increased urinary IP-10 and IFN-γ.
- The induced Th1 chemokines contribute to an anti-angiogenic urinary microenvironment, potentially inhibiting tumor growth.
- Further research is warranted to validate IP-10 as a prognostic biomarker for bladder cancer and its response to BCG immunotherapy.
Related Concept Videos
01:21Chemotaxis and Direction of Cell Migration
6.0K
Cells can detect chemical cues in their environment and reorganize the cytoskeleton to migrate toward them or away from them. This directional migration, called chemotaxis, is essential during embryogenesis and development, immune response, tissue repair and regeneration, and reproduction. These chemical cues can either attract or repel the cell's movement. For example, axon development is determined by a combination of chemoattractants and chemorepellents that direct the growing axon...
6.0K
02:17The Tumor Microenvironment
8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
691